Rani Therapeutics Holdings, Inc. (RANI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rani Therapeutics Holdings, Inc. (RANI) trades at $0.82 with AI Score 19/100 (Grade F). Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics using its RaniPill capsule technology. Market cap: $53.36M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for RANI: RANI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RANI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RANI: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Rani Therapeutics Holdings, Inc. (RANI) Healthcare & Pipeline Overview
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company specializing in the development of orally administered biologics through its proprietary RaniPill capsule. This innovative platform targets to transform drug delivery by replacing traditional injections, positioning the company within the competitive biotechnology sector focused on novel drug delivery systems.
What Is the Investment Thesis for RANI?
Rani Therapeutics presents a notable research candidate due to its innovative RaniPill capsule technology, which aims to transform the delivery of biologics. The company's pipeline includes multiple drug candidates targeting large and growing markets, such as neuroendocrine tumors, psoriatic arthritis, osteoporosis, and diabetes. Successful clinical trials and regulatory approvals could drive significant value creation. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from established pharmaceutical companies. With a market capitalization of $53.36M and a gross margin of 75.0%, Rani Therapeutics is positioned for growth if it can successfully advance its pipeline and commercialize its technology. Upcoming clinical trial results for RT-101 and RT-105 are key catalysts to watch. The company's high profit margin of -1817.1% indicates that it is still in the development stage.
Based on FMP financials and quantitative analysis
RANI Key Highlights
- Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery of biologics, offering a potential alternative to injections.
- The company's RaniPill capsule technology is designed to replace subcutaneous or IV injections, potentially improving patient compliance and reducing healthcare costs.
- Rani Therapeutics has a diverse pipeline of drug candidates targeting various chronic diseases, including neuroendocrine tumors, psoriatic arthritis, osteoporosis, and diabetes.
- RT-101, an octreotide formulation, has completed Phase I clinical trials for the treatment of neuroendocrine tumors and acromegaly, marking a significant milestone.
- The company's gross margin is 75.0%, reflecting the potential profitability of its technology upon successful commercialization, although its profit margin is -1817.1%.
Who Are RANI's Competitors?
RANI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVO Novo Nordisk A/S | $49.28 | -2.27% | $219.01B | 51 |
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| VRTX Vertex Pharmaceuticals Incorporated | $528.88 | +0.16% | $134.23B | 99 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RANI's Key Strengths?
- Innovative RaniPill capsule technology.
- Potential to replace injections with oral dosing.
- Diverse pipeline of drug candidates.
- Strong intellectual property portfolio.
What Are RANI's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- High R&D spending.
- Limited financial resources.
What Could Drive RANI Stock Higher?
- Clinical trial results for RT-105 (anti-TNF-alpha antibody) in psoriatic arthritis are expected in late 2026.
- Continued development and advancement of the RaniPill capsule technology.
- Potential partnerships and licensing agreements with pharmaceutical companies are anticipated in 2027.
- Expansion of the RaniPill platform to new therapeutic areas.
What Are the Key Risks for RANI?
- Financial-distress signal — its Altman Z-Score of -3.26 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures could delay or halt the development of its drug candidates.
- Regulatory hurdles and delays in obtaining marketing approval.
- Competition from established pharmaceutical companies with greater resources.
- Patent expiration and loss of exclusivity for its RaniPill capsule technology.
- Reliance on third-party manufacturers for the production of its drug candidates.
What Are the Growth Opportunities for RANI?
- Expansion of RaniPill Platform: Rani Therapeutics has the opportunity to expand the application of its RaniPill capsule technology to deliver a wider range of biologics. This includes exploring partnerships with pharmaceutical companies to develop oral formulations of their injectable drugs. The global drug delivery market is projected to reach $228 billion by 2027, providing a substantial market opportunity for Rani Therapeutics to capture through strategic collaborations and platform innovation. Timeline: Ongoing.
- Advancement of RT-105 for Psoriatic Arthritis: Rani Therapeutics can drive growth by successfully advancing RT-105, an anti-TNF-alpha antibody, through clinical trials for the treatment of psoriatic arthritis. The psoriatic arthritis market is expected to reach $14.5 billion by 2028, offering a significant revenue opportunity for Rani Therapeutics if RT-105 proves to be safe and effective. Timeline: 2026-2028.
- Development of RT-102 for Osteoporosis: The development of RT-102, a parathyroid hormone for the treatment of osteoporosis, presents another growth opportunity. The osteoporosis market is projected to reach $15.2 billion by 2027. Successful preclinical and clinical development of RT-102 could position Rani Therapeutics as a key player in this market. Timeline: 2027-2029.
- Partnerships and Licensing Agreements: Rani Therapeutics can accelerate its growth by establishing partnerships and licensing agreements with pharmaceutical companies to co-develop and commercialize its drug candidates. This would provide the company with additional funding and expertise, while also expanding its market reach. The pharmaceutical industry is increasingly focused on collaborations to drive innovation, creating opportunities for Rani Therapeutics to leverage its technology. Timeline: Ongoing.
- Expansion into New Therapeutic Areas: Rani Therapeutics has the potential to expand its focus beyond its current pipeline and explore new therapeutic areas where the RaniPill capsule technology can be applied. This could include developing oral formulations of vaccines, gene therapies, and other advanced therapeutics. The market for these therapies is growing rapidly, offering a long-term growth opportunity for Rani Therapeutics. Timeline: 2028+
What Opportunities Does RANI Have?
- Partnerships with pharmaceutical companies.
- Expansion into new therapeutic areas.
- Regulatory approval of its drug candidates.
- Growing market for biologics.
What Threats Does RANI Face?
- Competition from established pharmaceutical companies.
- Clinical trial failures.
- Regulatory hurdles.
- Patent expiration.
What Are RANI's Competitive Advantages?
- Proprietary RaniPill capsule technology protected by patents.
- First-mover advantage in the oral delivery of biologics.
- Strong intellectual property portfolio.
- Experienced management team with expertise in drug delivery and biotechnology.
- Established partnerships with leading pharmaceutical companies.
What Does RANI Do?
Rani Therapeutics Holdings, Inc., founded in 2012 and headquartered in San Jose, California, is a clinical-stage biotherapeutics company focused on developing orally administered biologics. The company's core technology is the RaniPill capsule, a platform designed to replace subcutaneous or intravenous injections of biologics with oral dosing. This innovative approach aims to improve patient compliance, reduce healthcare costs, and enhance the overall patient experience. The RaniPill capsule is designed to deliver biologics directly into the small intestine, where they can be absorbed into the bloodstream. Rani Therapeutics' product pipeline includes several drug candidates targeting a range of chronic diseases. RT-101, an octreotide formulation, has completed Phase I clinical trials for the treatment of neuroendocrine tumors and acromegaly. RT-105 is an anti-TNF-alpha antibody being developed to treat psoriatic arthritis. Other pipeline candidates include RT-102, a parathyroid hormone for osteoporosis; RT-109, a human growth hormone for growth hormone deficiency; RT-110, a parathyroid hormone for hypoparathyroidism; and RT-106, a basal insulin for type 2 diabetes. The company's focus on oral delivery of biologics addresses a significant unmet need in the pharmaceutical industry, offering a potentially disruptive alternative to traditional injectable therapies.
What Products and Services Does RANI Offer?
- Develops the RaniPill capsule, a platform for oral delivery of biologics.
- Aims to replace subcutaneous or IV injections with oral dosing.
- Focuses on improving patient compliance and reducing healthcare costs.
- Develops RT-101 (octreotide) for neuroendocrine tumors and acromegaly.
- Develops RT-105 (anti-TNF-alpha antibody) for psoriatic arthritis.
- Develops RT-102 (parathyroid hormone) for osteoporosis.
- Develops RT-109 (human growth hormone) for growth hormone deficiency.
- Develops RT-106 (basal insulin) for type 2 diabetes.
How Does RANI Make Money?
- Develops and patents the RaniPill capsule technology.
- Out-licenses the RaniPill technology to pharmaceutical companies.
- Conducts clinical trials to validate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its drug candidates.
- Commercializes its drug candidates through partnerships or direct sales.
What Industry Does RANI Operate In?
Rani Therapeutics operates in the biotechnology industry, which is characterized by rapid innovation, high R&D spending, and stringent regulatory requirements. The market for biologics is growing rapidly, driven by the increasing prevalence of chronic diseases and the development of novel therapies. Rani Therapeutics' focus on oral delivery of biologics addresses a significant unmet need, as many biologics are currently administered via injection. The company faces competition from established pharmaceutical companies and other biotechnology firms developing alternative drug delivery technologies. The biotechnology industry is expected to continue to grow, driven by advances in genomics, proteomics, and personalized medicine.
Who Are RANI's Key Customers?
- Pharmaceutical companies seeking to develop oral formulations of their injectable drugs.
- Patients with chronic diseases who prefer oral dosing over injections.
- Healthcare providers looking to improve patient compliance and reduce healthcare costs.
- Payers seeking to reduce the cost of biologics.
FY2026 estForward Outlook
Wall Street analysts project Rani Therapeutics Holdings, Inc. revenue of about $4.1M for fiscal 2026, with EPS near $-0.19. The estimate reflects 3 contributing analysts.
F-Score 4/9Financial Health
Rani Therapeutics Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -3.26 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -56.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -33.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.40 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -21.0%, the inverse of the P/E and a quick read on earnings relative to price.
Rani Therapeutics Holdings, Inc. (RANI) Valuation Context
Valued at $53.36M, RANI is classified as a micro-cap stock. Relative to its peer group, RANI's quantitative score of 19/100 is below the peer average of 81/100.
Company Profile
Rani Therapeutics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Jose, US. The company is led by CEO Talat Imran. RANI has traded publicly since 2021.
RANI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Rani Therapeutics' future, indicating that executives believe in the company's potential.
- Community sentiment has shifted positively as recent announcements about product developments have sparked excitement among investors.
- The market is responding favorably to Rani's innovative approach to drug delivery, which could disrupt traditional methods and attract attention.
- Increased media coverage and analyst interest have raised visibility, potentially drawing in new investors and creating bullish momentum.
Bear Case
- Concerns about the company's ability to execute its ambitious plans have surfaced, with skeptics questioning the scalability of its technology.
- Recent social sentiment reflects caution, as some investors express doubts about the company’s long-term profitability and market competition.
- The biotech sector's volatility continues to weigh on investor sentiment, leading to a cautious outlook for Rani amidst broader market uncertainties.
- Insider selling in the past has raised red flags, causing some community members to reconsider their positions and leading to bearish sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RANI Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 3, 2023
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Sep 29, 2023
RANI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RANI.
Price Targets
Wall Street price target analysis for RANI.
RANI MoonshotScore
What does this score mean?
The MoonshotScore rates RANI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Talat Imran
CEO
Talat Imran is the Chief Executive Officer of Rani Therapeutics. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Rani Therapeutics, he held leadership positions at various companies, focusing on drug development, commercialization, and strategic partnerships. He has a proven track record of building and scaling successful companies in the healthcare sector. His expertise spans across multiple therapeutic areas, including endocrinology, oncology, and immunology. He is managing 105 employees at Rani Therapeutics.
Track Record: Under Talat Imran's leadership, Rani Therapeutics has advanced its RaniPill capsule technology and expanded its pipeline of drug candidates. He has overseen the completion of Phase I clinical trials for RT-101 and has secured partnerships with pharmaceutical companies to co-develop and commercialize its products. He has also led the company through multiple rounds of financing, raising capital to support its research and development efforts.
RANI Healthcare Stock FAQ
What does Rani Therapeutics Holdings, Inc. do?
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on developing orally administered biologics using its proprietary RaniPill capsule technology. The RaniPill capsule is designed to replace subcutaneous or IV injections of biologics with oral dosing, aiming to improve patient compliance, reduce healthcare costs, and enhance the overall patient experience. The company's pipeline includes drug candidates targeting various chronic diseases, such as neuroendocrine tumors, psoriatic arthritis, osteoporosis, and diabetes. Rani Therapeutics' innovative approach addresses a significant unmet need in the pharmaceutical industry.
What do analysts say about RANI stock?
Analyst coverage of Rani Therapeutics Holdings, Inc. is still emerging, reflecting its clinical-stage status. Key valuation metrics focus on the potential of the RaniPill technology and the success of its clinical trials. Growth considerations center on the advancement of its pipeline, regulatory approvals, and partnerships with pharmaceutical companies. Analyst consensus is cautiously optimistic, acknowledging the potential of the technology but also recognizing the risks associated with clinical development and regulatory pathways. No buy or sell recommendations are being made.
What are the main risks for RANI?
Rani Therapeutics faces several key risks inherent to its clinical-stage status and the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could delay or halt the development of its drug candidates. Regulatory hurdles and delays in obtaining marketing approval pose another challenge. Competition from established pharmaceutical companies with greater resources and existing therapies is also a concern. Additionally, patent expiration and loss of exclusivity for its RaniPill capsule technology could impact its long-term competitive advantage. Reliance on third-party manufacturers introduces supply chain and quality control risks.
How does Rani Therapeutics Holdings, Inc. navigate regulatory approval processes?
As a clinical-stage biopharmaceutical company, Rani Therapeutics' success hinges on navigating complex regulatory pathways. The company works closely with regulatory agencies like the FDA to ensure compliance with clinical trial protocols and data requirements. Rani Therapeutics focuses on robust data collection and analysis to support its regulatory submissions. The company also monitors changes in regulatory guidelines and adapts its strategies accordingly. Successful navigation of these processes is crucial for securing marketing approval and commercializing its drug candidates.
How does Rani Therapeutics Holdings, Inc. manage patent expiration risks?
Rani Therapeutics manages patent expiration risks through a multi-faceted approach. The company actively seeks to extend the patent life of its RaniPill capsule technology and drug candidates by filing new patent applications for innovations and improvements. Rani Therapeutics also explores strategies such as formulation patents and method-of-use patents to protect its products beyond the initial patent term. Additionally, the company continuously monitors the competitive landscape and anticipates potential challenges from biosimilar or generic versions of its therapies. Proactive management of intellectual property is essential for maintaining a competitive advantage.
What are the key factors to evaluate for RANI?
Rani Therapeutics Holdings, Inc. (RANI) holds an AI score of 19/100 (low). Not financial advice.
How frequently does RANI data refresh on this page?
RANI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RANI's recent stock price performance?
Rani Therapeutics Holdings, Inc. (RANI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative RaniPill capsule technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain and can impact the company's prospects.
- Analyst opinions may vary and should be considered as part of a broader research process.